News Breaks |
|
|
| January 29, 2013 |
| 08:17 EDT |  | CELG | Acceleron Pharma and Celgene initiate phase 2 study of ACE-536
Acceleron Pharma announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes, or MDS. MDS are a group of hematologic malignancies of the bone marrow that result in low levels of one or more types of blood cells resulting most commonly in severe and chronic anemia. Acceleron is developing ACE-536 in a global collaboration with Celgene. Acceleron earned a $10M milestone for initiating this phase 2 study and is still eligible to receive development, regulatory and commercial milestones of up to $200M for the ACE-536 program. |
|
|
News For CELG From The Last 14 Days Check below for free stories on CELG the last two weeks. |
|
|
| May 17, 2013 |
| 05:51 EDT |  | CELG | Stocks with implied volatility movement; CBST CELG
 Subscribe for More Information |
|
| May 16, 2013 |
| 15:11 EDT |  | CELG | Celgene management to meet with JPMorgan
Subscribe for More Information |
|
| 11:50 EDT | | CELG | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| May 7, 2013 |
| 07:18 EDT |  | CELG | Barclays has increased confidence in Celgene's re-filing of Revlimid
Subscribe for More Information |
|
| May 6, 2013 |
| 14:33 EDT | | CELG | Celgene's apremilast had statistical significance for primary endpoint
Subscribe for More Information |
|
|
|
|
|
